MedTrace Logo

Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID

NCT07714889 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2026-07-29

No results posted yet for this study

Summary

This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression. This study will evaluate the completion rates of the Toivoa-004 program and survey the user's experience upon completion. Changes in anxiety and depression scores will be monitored during the study.

Conditions

Interventions

DEVICE

Rauha® Digital Therapeutic Platform (Toivoa-004)

A coach-delivered, WCAG 2.2 AA-accessible digital therapeutic targeting anxiety and depression symptom management in adults with clinically documented Long COVID. The platform integrates evidence-based behavioral health content delivered via the Rauha® Coach application.

Sponsors & Collaborators

  • National Institute of Nursing Research (NINR)

    collaborator NIH

  • Toivoa Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714889 on ClinicalTrials.gov